The Missing Majority: Why Older Adults Remain the Weakest Link in Oncology Trial Evidence
Over the past decade, oncology has achieved a level of biological precision that would have been difficult to imagine even twenty years ago. Molecular stratification has redefined disease taxonomy, biomarker-driven therapies have reshaped treatment algorithms, and adaptive trial designs have...
